Cargando…
Identifying protein–protein interactions in somatic hypermutation
Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far les...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213056/ https://www.ncbi.nlm.nih.gov/pubmed/15710655 http://dx.doi.org/10.1084/jem.20050161 |
_version_ | 1782148815775596544 |
---|---|
author | Goodman, Myron F. Scharff, Matthew D. |
author_facet | Goodman, Myron F. Scharff, Matthew D. |
author_sort | Goodman, Myron F. |
collection | PubMed |
description | Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far less prominent, but change appears imminent. Here we comment on how, when, and why biochemistry is likely to emerge from the shadows and into the spotlight to elucidate how the somatic mutation of antibody variable (V) regions is generated. |
format | Text |
id | pubmed-2213056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22130562008-03-11 Identifying protein–protein interactions in somatic hypermutation Goodman, Myron F. Scharff, Matthew D. J Exp Med Commentary Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far less prominent, but change appears imminent. Here we comment on how, when, and why biochemistry is likely to emerge from the shadows and into the spotlight to elucidate how the somatic mutation of antibody variable (V) regions is generated. The Rockefeller University Press 2005-02-21 /pmc/articles/PMC2213056/ /pubmed/15710655 http://dx.doi.org/10.1084/jem.20050161 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Commentary Goodman, Myron F. Scharff, Matthew D. Identifying protein–protein interactions in somatic hypermutation |
title | Identifying protein–protein interactions in somatic hypermutation |
title_full | Identifying protein–protein interactions in somatic hypermutation |
title_fullStr | Identifying protein–protein interactions in somatic hypermutation |
title_full_unstemmed | Identifying protein–protein interactions in somatic hypermutation |
title_short | Identifying protein–protein interactions in somatic hypermutation |
title_sort | identifying protein–protein interactions in somatic hypermutation |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213056/ https://www.ncbi.nlm.nih.gov/pubmed/15710655 http://dx.doi.org/10.1084/jem.20050161 |
work_keys_str_mv | AT goodmanmyronf identifyingproteinproteininteractionsinsomatichypermutation AT scharffmatthewd identifyingproteinproteininteractionsinsomatichypermutation |